Short Interest in Oxford BioMedica (OTCMKTS:OXBDF) Drops By 23.2%

Oxford BioMedica (OTCMKTS:OXBDF) saw a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 60,810 shares, a decline of 23.2% from the February 12th total of 79,226 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 22,953 shares, the short-interest ratio is currently 2.6 days. Based on an average daily trading volume, of 22,953 shares, the short-interest ratio is currently 2.6 days. Currently, 0.1% of the company’s stock are short sold.

Oxford BioMedica Stock Performance

Shares of OXBDF remained flat at $8.17 during mid-day trading on Monday. The company has a debt-to-equity ratio of 3.08, a quick ratio of 1.67 and a current ratio of 1.89. Oxford BioMedica has a 1 year low of $3.15 and a 1 year high of $12.61. The business’s 50-day moving average price is $10.54 and its two-hundred day moving average price is $8.96.

Oxford BioMedica Company Profile

Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.

In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.